Get the Stockscreener App
5.64
5.42%
0.29
After Hours:
5.63
-0.010
-0.18%
Ardelyx Inc stock is traded at $5.64, with a volume of 2.50M.
It is up +5.42% in the last 24 hours and down -14.02% over the past month.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$5.35
Open:
$5.45
24h Volume:
2.50M
Relative Volume:
0.55
Market Cap:
$1.38B
Revenue:
$407.32M
Net Income/Loss:
$-61.60M
P/E Ratio:
-21.89
EPS:
-0.2576
Net Cash Flow:
$-43.98M
1W Performance:
+1.62%
1M Performance:
-14.02%
6M Performance:
-5.37%
1Y Performance:
+8.67%
1-Day Range:
$5.45
$5.73
1-Week Range:
$5.00
$5.73
52-Week Range:
$3.21
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
5.64 | 1.31B | 407.32M | -61.60M | -43.98M | -0.2576 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-03-25 | Resumed | Raymond James | Strong Buy |
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| May-02-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
| Mar-04-25 | Initiated | BTIG Research | Buy |
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
Piper Sandler Maintains a Hold Rating on Ardelyx (ARDX) - MSN
Ardelyx's post-earnings decline attributed to concerns over Ibsrela outlook - MSN
Ardelyx gains after insider purchase, LPGA marketing deal - MSN
ARDX SEC FilingsArdelyx 10-K, 10-Q, 8-K Forms - Stock Titan
ARDX stock is down pre-market after Q4 earnings miss, so why did this firm just hike price target by 80%? - MSN
Can Ardelyx Inc stock outperform in a bear market2026 Short Interest & Stepwise Trade Execution Plans - baoquankhu1.vn
ARDX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Insider Selling: Ardelyx (NASDAQ:ARDX) CEO Sells 41,666 Shares of Stock - MarketBeat
Raab, Ardelyx CEO, sells $243k in ARDX stock By Investing.com - Investing.com Canada
Raab, Ardelyx CEO, sells $243k in ARDX stock - Investing.com
Ardelyx (ARDX) CEO exercises options, sells 41,666 shares under plan - Stock Titan
Ardelyx, Inc. Opens with 8.38% Gain, Contrasting Recent Performance Trends - Markets Mojo
Ardelyx, Inc. Hits Day High with Strong 14.49% Intraday Surge - Markets Mojo
ARDX Stock Price, Quote & Chart | ARDELYX INC (NASDAQ:ARDX) - ChartMill
Will Ardelyx’s (ARDX) IBSRELA Data Shift Its Competitive Position In IBS-C Treatments? - simplywall.st
Leerink Maintains Outperform on Ardelyx, Inc (ARDX) March 12, 2026 - Meyka
Leerink Partners reiterates Ardelyx stock rating on pipeline progress - Investing.com
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award - The Manila Times
Five kidney disease advocates honored for decades of patient support - Stock Titan
Breakout Move: How does Ardelyx Inc correlate with Nasdaq2026 Highlights & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Ardelyx Touts IBSRELA’s 73% Growth, Reaffirms $1B 2029 Goal and Details CIC Phase III Plan - MarketBeat
Ardelyx at Leerink Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada
ARDX: IBSRELA targets $1B sales by 2029, with pipeline and commercial growth fueled by strong execution - TradingView
Assessing Ardelyx (ARDX) Valuation After Recent Share Price Weakness - Yahoo Finance
Ardelyx (ARDX) Valuation Check After Recent Share Price Weakness And Growth Expectations - simplywall.st
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C - The Manila Times
Ardelyx, Inc. Publishes Data Supporting Tenapanor's Rapid and Sustained Relief for IBS-C in Peer-Reviewed Journal - Quiver Quantitative
Ardelyx Announces Publication of a Review Article - GlobeNewswire
Is Ardelyx (ARDX) Pricing In Its Potential After Recent Share Price Weakness - Yahoo Finance
Is Ardelyx (ARDX) Pricing Reflect Its DCF Upside After Recent Share Price Volatility - simplywall.st
Is Ardelyx Inc. (41X) stock bottoming after sell off2026 Buyback Activity & Technical Pattern Based Buy Signals - Naître et grandir
Ardelyx, Inc. (NASDAQ:ARDX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Is Ardelyx’s 2026 IBSRELA Outlook Altering The Investment Case For Ardelyx (ARDX)? - Sahm
Vanguard Group Inc. Boosts Holdings in Ardelyx, Inc. $ARDX - MarketBeat
Ardelyx to Participate in Upcoming Investor Conferences - GlobeNewswire
ARDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Ardelyx (NASDAQ:ARDX) Stock Passes Below 200-Day Moving AverageWhat's Next? - MarketBeat
Ardelyx LPGA Partnership Puts Spotlight On Women’s Digestive Health And Growth - simplywall.st
Assessing Ardelyx (ARDX) Valuation After Strong 2025 Results And 2026 Growth Guidance - simplywall.st
Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership - The Globe and Mail
Revisiting ArdelyxInsider Weekends (NASDAQ:ARDX) - Seeking Alpha
ARDX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Ardelyx, Inc. (ARDX) Investor Outlook: Analysts See A Potential 142% Upside - DirectorsTalk Interviews
Ardelyx goes full swing with the LPGA for IBS-C awareness - Medical Marketing and Media
ARDELYX (NASDAQ: ARDX) CEO Raab sells 41,666 shares after option exercise - Stock Titan
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):